BioNTech SE reports recurring developments as a Germany-based biotechnology company whose ADSs trade on Nasdaq. Company news centers on oncology pipeline progress across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, including lung cancer programs such as pumitamig and gotistobart, as well as COVID-19 vaccine activity tied to its commercial vaccine franchise.
Updates also cover quarterly and annual financial results, research and development spending, corporate presentations, capital allocation actions such as ADS repurchase authorizations, and shareholder meeting or governance matters. BioNTech news frequently links clinical data, partnership activity and operating priorities to its broader objective of building a multi-product biotechnology business.
BioNTech (BNTX) and DualityBio announced that trastuzumab pamirtecan met the primary endpoint in the global Phase 3 DYNASTY-Breast02 breast cancer trial. Treatment delivered a statistically significant but modest improvement in progression-free survival, the time before disease worsens, versus investigator-selected chemotherapy in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer after endocrine therapy. Overall survival data were immature at the interim analysis.
Interstitial lung disease occurred more frequently than in prior trastuzumab pamirtecan trials. Most cases were Grade 1–2, but a small proportion of patients experienced severe or fatal Grade 3–5 events. Otherwise, safety was consistent with prior trials, with no new safety signals. The companies said available efficacy and safety data suggest limited potential patient benefit in this treatment setting; they will discuss the data and determine next steps.
BioNTech (BNTX) and Bristol Myers Squibb reported a 36.7% confirmed response rate for pumitamig plus docetaxel in Phase 2 lung cancer testing. ROSETTA Lung-107 studied metastatic non-small cell lung cancer after progression on first-line immunotherapy plus chemotherapy. At the July 10, 2026 cutoff, 30 patients were evaluable for response; disease control was 90.0%, with responses across PD-L1 expression levels and both tumor types.
Among 50 treated patients, early median progression-free survival, the time without disease worsening or death, was 6.9 months. Median follow-up was 12.2 weeks. The open-label, single-arm study had no concurrent control group. Pumitamig-related adverse events occurred in 52.0% of patients, with grade 3 or higher events in 18.0% and discontinuations in 8.0%. No pumitamig-related deaths or dose-limiting toxicities occurred. The companies plan to use these data to inform further second-line development.
BioNTech (BNTX) entered a collaboration and supply agreement with Gilead Sciences to evaluate pumitamig combined with sacituzumab govitecan in breast cancer. BioNTech and Bristol Myers Squibb plan to adapt the ongoing Phase 3 ROSETTA Breast-01 trial by replacing chemotherapy with sacituzumab govitecan, an antibody-drug conjugate that delivers treatment to targeted cells. The change requires regulatory authority approval.
The trial targets first-line treatment of locally advanced or metastatic triple-negative breast cancer with low or negative PD-L1 expression (CPS < 10). BioNTech will remain sponsor and trial leader; Gilead will supply sacituzumab govitecan. Pumitamig is jointly developed with Bristol Myers Squibb. The companies plan additional Phase 3 combination trials across multiple solid tumors. The proposed combination is investigational, and its safety and efficacy have not been established.
BioNTech (Nasdaq: BNTX) will announce its third-quarter 2026 financial results and provide a corporate update on November 3, 2026. A conference call and webcast will take place that day at 8:00 a.m. ET (2:00 p.m. CET). A webcast replay will be available shortly afterward and archived on the company’s website for 30 days following the call.
BioNTech (Nasdaq: BNTX) will present oncology clinical data at ESMO in Madrid, October 23–27, 2026, including first results from ROSETTA Lung-107. The global Phase 2 trial evaluates pumitamig plus docetaxel in metastatic non-small cell lung cancer after progression on immunotherapy plus chemotherapy.
BioNTech describes preliminary antitumor activity and manageable safety for pumitamig plus elfetabart drozuntecan in advanced solid tumors and for pumitamig plus FOLFIRI chemotherapy in previously treated neuroendocrine neoplasms. A subgroup analysis of two Phase 2 trials found systemic efficacy generally consistent in patients with and without brain metastases. The company says these early data suggest activity against tumors within the brain.
BioNTech (BNTX) reported that its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab missed its first dual primary endpoint.
The combination did not demonstrate a statistically significant improvement in progression-free survival, the time patients live without disease worsening, versus pembrolizumab alone. The trial evaluates first-line treatment for unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma expressing PD-L1. The independent monitoring committee recommended continuing as planned to assess overall survival, how long patients live. Under the pre-specified statistical design, a statistically significant overall survival improvement would establish a positive trial outcome despite the missed endpoint. BioNTech remains blinded to ongoing trial data. BNT113 received FDA Fast Track Designation in January 2026.
BioNTech (BNTX) and OncoC4 reported updated Phase 3 PRESERVE-003 data showing gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous NSCLC.
In non-pivotal stage 1, 87 metastatic squamous NSCLC patients whose disease had progressed on prior immunotherapy and chemotherapy were randomized to gotistobart monotherapy (N=45) or docetaxel (N=42). At a July 17, 2026 data cut-off with 25.4 months median follow-up, median overall survival was 18.5 months with gotistobart versus 10.0 months with docetaxel (hazard ratio 0.56; nominal p=0.0295). Grade ≥3 treatment-related adverse events occurred in 44.4% of gotistobart patients and 48.8% of docetaxel patients, with a safety profile described as manageable. The pivotal stage 2 of PRESERVE-003, with overall survival as the primary endpoint, is ongoing at more than 160 global sites.
BioNTech (Nasdaq: BNTX) and Pfizer announced U.S. FDA approval of a supplemental Biologics License Application for their 2026-2027 COVID-19 vaccine formula COMIRNATY XFG, targeting the XFG variant. The vaccine is authorized for adults 65+ and for individuals 5–64 years with at least one high-risk underlying condition.
According to Pfizer and BioNTech, approval is supported by clinical, non-clinical, real-world, manufacturing and quality data, including non-clinical results showing strong immune responses against XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 and other contemporary SARS-CoV-2 lineages. The XFG variant was selected in line with FDA guidance for U.S. vaccines beginning fall 2026. Shipping of the new season’s vaccine to U.S. pharmacies, hospitals and clinics will begin immediately. The companies note more than 5 billion COMIRNATY doses have been distributed globally, with a favorable safety and efficacy profile supported by extensive evidence.
BioNTech (Nasdaq: BNTX) will present new clinical data from its lung cancer pipeline at the IASLC 2026 World Conference on Lung Cancer in Seoul, Republic of Korea, from September 12‑15, 2026. Key assets include pumitamig (BNT327/BMS986545) and gotistobart (BNT316/ONC‑392), alongside mRNA-based immunotherapies.
Highlights feature the first global lung cancer data for the novel-novel combination of pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, with B7H3-targeting ADC elfetabart drozuntecan (BNT324/DB‑1311) in a Phase 1/2 trial in advanced/metastatic SCLC and NSCLC, plus updated overall survival from the Phase 3 PRESERVE‑003 trial of gotistobart in second‑ and later‑line squamous NSCLC after PD‑(L)1 progression.
According to BioNTech, the company is running 16 ongoing lung cancer trials, including five Phase 3 and two novel-novel combination studies, covering multiple subtypes, biomarkers and treatment settings.
BioNTech (Nasdaq:BNTX) reported Q2 2026 revenues of €105.6 million, down from €260.8 million, and a net loss of €820.8 million (adjusted net loss €562.3 million; diluted loss per share €3.24, adjusted €2.22). Year‑to‑date revenues were €223.7 million with a net loss of €1,352.7 million.
BioNTech revised 2026 revenue guidance to €1.6–1.9 billion (from €2.0–2.3 billion) and lowered adjusted R&D guidance to €2.0–2.3 billion, keeping adjusted SG&A at €700–800 million. Cash, cash equivalents and security investments totaled €16.6 billion, and a share repurchase program of up to $1.0 billion is underway. The company highlighted 14 ongoing pivotal trials, multiple late‑stage oncology milestones, approval of an XFG variant‑adapted COVID‑19 vaccine in the EU, and the appointment of Guido Oelkers as CEO effective by February 1, 2027.